Patients with high-risk locally advanced rectal cancer face a tough battle. Their tumors have grown into nearby tissues or spread to lymph nodes. Doctors often add chemotherapy to radiation to help kill cancer cells. This trial asked if adding oxaliplatin to a standard regimen would make a real difference for these patients.
The study involved 505 people across multiple centers. They received long-course radiation combined with either capecitabine alone or capecitabine plus oxaliplatin. The goal was to see if the stronger drug mix would lead to better outcomes without causing too much harm.
The results showed that the group taking oxaliplatin had more marked tumor shrinkage. This is a sign that the treatment worked well on the cancer cells. However, when looking at the most important measure of success, three-year disease-free survival, there was no significant difference between the two groups. Adding the extra drug did not lower the risk of the cancer coming back or spreading.
Safety was also a key concern. The group taking oxaliplatin experienced slightly more severe side effects, though this difference was not statistically significant. The study found that while the stronger drug mix made tumors shrink more, it did not translate into a long-term survival benefit for patients with this specific type of cancer.